Literature DB >> 17383807

Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium.

Felix K-H Chun1, Alberto Briganti, Andrea Gallina, Georg C Hutterer, Shahrokh F Shariat, Elie Antebie, Jochen Walz, Claus G Roehrborn, Andrea Salonia, Patrizio Rigatti, Fred Saad, Hartwig Huland, Francesco Montorsi, Markus Graefen, Pierre I Karakiewicz.   

Abstract

OBJECTIVES: The contemporary ability of prostate-specific antigen (PSA) to predict pathologic stage in men with localized prostate cancer was recently questioned.
METHODS: We quantified the added value related to the addition of pretreatment PSA to established pathologic stage predictors (namely clinical stage and biopsy Gleason sum) in 5921 consecutive radical prostatectomy (RP) patients. Univariable and multivariable logistic regression analyses predicting pathologic stage (extracapsular extension [ECE], seminal vesicle invasion [SVI], lymph node invasion [LNI], and organ-confined disease [OC]) were stratified according to four time quartiles. The gain in predictive accuracy (PA) related to the inclusion of PSA to multivariable models was quantified by using the area under the curve method.
RESULTS: Temporal analyses showed a decrease in PSA levels over the study years (p<0.001). Conversely, the rate of nonpalpable disease and the rate of biopsy Gleason sum < or =6 increased over time (all p<0.001). At RP, the rate of OC increased over time, while the rate of ECE and SVI decreased over time (all p<0.001). The rate of LNI remained stable (p=0.1). In multivariable models, PSA represented an independent predictor of all pathologic stages over time (all p<0.03), except for ECE in the first and last time quartiles. The addition of PSA significantly increased the multivariable PA of all models predicting pathologic stages over time (all p<0.03), except for ECE predictions in the first quartile (p=0.1).
CONCLUSIONS: In the new millennium, PSA has not lost its ability to accurately predict the pathologic stage in contemporary patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17383807     DOI: 10.1016/j.eururo.2007.03.018

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  3 in total

1.  Validation of revised Epstein's criteria for insignificant prostate cancer prediction in a Greek subpopulation.

Authors:  Κ Chondros; Ν Karpathakis; Ι Heretis; Ε Mavromanolakis; N Chondros; F Sofras; C Mamoulakis
Journal:  Hippokratia       Date:  2015 Jan-Mar       Impact factor: 0.471

2.  Are clinically insignificant prostate cancers really insignificant among Korean men?

Authors:  Chan Dong Yeom; Seung Hwan Lee; Kyung Kgi Park; Sang Un Park; Byung Ha Chung
Journal:  Yonsei Med J       Date:  2012-03       Impact factor: 2.759

Review 3.  The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements.

Authors:  Pierre-Olivier Gaudreau; John Stagg; Denis Soulières; Fred Saad
Journal:  Biomark Cancer       Date:  2016-05-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.